Proton therapy costs $45,000-$55,000 in China vs $100,000-$200,000 in the US. China operates 11-14 proton centers with published survival data matching international benchmarks.
Proton therapy in China costs $45,000 to $55,000 for a full treatment course, compared with $100,000 to $200,000 in the United States, according to Healtra's China proton therapy cost guide (opens in new tab) and a 2022 study in PubMed analyzing US proton therapy list prices (opens in new tab). That's a 60-70% savings on one of the most advanced cancer treatments available.
China now operates 11 to 14 proton therapy centers with an additional 12 under construction and 4 in planning, according to the Particle Therapy Co-Operative Group (PTCOG) (opens in new tab). The country also operates 3 heavy ion therapy centers - a technology that only a handful of nations offer - including the Gansu Wuwei Tumor Hospital, which has treated 1,820 patients across 40+ conditions (opens in new tab).
Prices and data current as of April 2026.
Cost Component | United States | China |
|---|---|---|
Full treatment course | $100,000-$200,000 | $45,000-$55,000 |
Per-session median (cash pay) | $4,700-$6,700 | $1,500-$2,500 |
Brain tumor (30 fractions) | $95,000-$120,000 | $40,000-$50,000 |
Head/neck (35 fractions) | $120,000-$165,000 | $45,000-$60,000 |
Savings | - | 60-70% |
US per-session pricing comes from a 2022 PubMed study (opens in new tab) that documented significant 5-10x variation across US proton centers. China pricing comes from Healtra's verified facility data (opens in new tab).
In the US, insurance coverage for proton therapy is inconsistent. Many insurers approve it only for specific indications (pediatric cancers, certain head/neck tumors) and deny coverage for more common cancers like prostate, despite clinical evidence. Cash-pay patients face the full $100,000-$200,000 bill.
The Shanghai Proton and Heavy Ion Center (SPHIC) opened in May 2015 and has become one of the most published particle therapy centers in the world. Here's what its outcome data shows:
Patient volume: By 2018, SPHIC had treated 1,263 patients (opens in new tab) - 654 head/neck, 205 thoracic, 404 abdominal/pelvic cases. The center reached its 500th patient within 19 months of opening.
Published survival data from peer-reviewed studies:
Cancer Type | Outcome | Rate | Source |
|---|---|---|---|
Prostate cancer (154 patients) | 3-year overall survival | 100% | |
Prostate cancer | 3-year biochemical control | 93% | |
Major salivary gland tumors | 3-year overall survival | 94.3% | |
Chordoma/chondrosarcoma | 2-year overall survival | 100% | |
Chordoma/chondrosarcoma | 2-year local control | 85.2% | |
Recurrent head/neck cancers | 1-year overall survival | 95.9% | |
Orbital malignancies | 2-year overall survival | 100% | |
High-grade glioma | 18-month overall survival | 72.8% |
10-year report: SPHIC reported a 69.5% overall 5-year survival rate (opens in new tab) across its entire patient population, with low rates of severe (Grade 3-4) adverse events.
International patients: Over 70 patients from foreign countries (opens in new tab) including the US and UK have been treated at SPHIC.
These aren't marketing claims. They're peer-reviewed results published in PubMed-indexed journals. You can search each study yourself on PubMed (opens in new tab).
SPHIC gets the most attention, but China's particle therapy infrastructure extends well beyond Shanghai.
Wanjie Proton Therapy Center (Zibo, Shandong): One of China's earliest proton facilities. Operated by IBA (Ion Beam Applications) (opens in new tab), the Belgian company that manufactures the majority of the world's proton therapy systems. The center was among the first in China to introduce PET, MRI, and Gamma Knife technology.
Shandong Proton Center (Jinan): Affiliated with Shandong Cancer Hospital and Institute. Treated its first patients on July 20, 2022 (opens in new tab). Features 3 treatment rooms with 360-degree rotational gantries plus a fixed-beam research room - a setup that matches the most advanced US centers.
Hefei Ion Medical Center: Operational and contributing to China's growing heavy ion therapy capacity.
Gansu Wuwei Tumor Hospital: Operates 2 heavy ion (carbon ion) therapy systems (opens in new tab) - unique worldwide. Has treated 1,820 patients covering 40+ medical conditions and serves international patients from Belgium, South Korea, and Australia.
Lanzhou Heavy Ion Hospital: Began operations November 15, 2024 (opens in new tab), making it China's newest heavy ion facility.
By the end of the decade, China expects to operate approximately 20 particle therapy facilities. A 2022 review in Frontiers in Oncology (opens in new tab) noted that by end of 2020, nearly 8,000 patients had been treated across China's 5 then-operational centers.
Proton therapy isn't for every cancer. Its advantage over conventional radiation is precision: protons deposit their energy at a specific depth (the Bragg peak) and stop, rather than passing through tissue like X-rays. This reduces radiation exposure to surrounding healthy organs.
According to Mayo Clinic (opens in new tab) and a 2024 review in JCO Oncology Practice (opens in new tab), proton therapy shows the strongest evidence for:
Pediatric cancers: The biggest win. Children's developing tissues are more sensitive to radiation damage. Proton therapy reduces long-term side effects including growth disorders, neurocognitive problems, hearing loss, and secondary cancers.
Head and neck cancers: Preserves vision, smell, taste, and swallowing function by limiting radiation to surrounding cranial nerves and tissues. Particularly valuable for re-irradiation of recurrent tumors where prior radiation has already stressed nearby organs.
Chordoma and chondrosarcoma (skull base/spine): These radiation-resistant tumors require high doses that would damage the spinal cord or brainstem with conventional radiation. Proton therapy allows safe dose escalation. SPHIC's published data shows 85.2% local control at 2 years (opens in new tab).
Liver cancer: Favorable local tumor control with proton therapy, particularly for hepatocellular carcinoma near critical liver structures.
Prostate cancer: Controversial in the US (insurers often deny coverage), but SPHIC published 100% 3-year overall survival with 93% biochemical control (opens in new tab) in 154 patients.
Brain tumors (glioma): SPHIC data shows 72.8% 18-month survival for high-grade glioma (opens in new tab), which is competitive with published benchmarks for this notoriously difficult cancer.
Proton therapy isn't a single visit. Plan for a multi-week stay.
Treatment schedule: 5 sessions per week (Monday-Friday), according to Johns Hopkins proton therapy protocols (opens in new tab).
Course length: Typically 4 to 8 weeks, with a range of 5-39 sessions depending on cancer type and treatment plan.
Cancer Type | Typical Sessions | Duration |
|---|---|---|
Prostate (hypofractionated) | 5 sessions | 1-2 weeks |
Prostate (standard) | 25-39 sessions | 5-8 weeks |
Brain tumor | ~30 fractions | ~6 weeks |
Head/neck | ~35 fractions | ~7 weeks |
Per-session time: The actual radiation takes 1-3 minutes. Setup and positioning takes 15-30 minutes per appointment. You'll spend more time getting positioned than receiving treatment.
Total in-country time: Plan for 5-9 weeks, including 1-2 days for pre-treatment evaluation, the treatment course, and brief post-treatment follow-up. Many international patients arrange furnished apartments near the treatment center for the duration.
The process for international patients involves a remote evaluation before you commit to travel.
Step 1: Remote evaluation. Send your medical records, pathology reports, and imaging (DICOM format) to the center's international department. SPHIC and other major centers accept remote evaluations and will tell you within 1-2 weeks whether proton therapy is appropriate for your case.
Step 2: Visa. Most Americans can enter China visa-free for up to 30 days. For treatment courses longer than 30 days, apply for an L-type (visitor) visa or an S1-type visa for extended stays. A medical visa guide for China (opens in new tab) recommends requesting an official invitation letter from the hospital.
Step 3: Travel and treatment. Major centers offer or coordinate airport transfers, accommodation assistance, and translation services. SPHIC's international department handles logistics for foreign patients.
Step 4: Follow-up. Post-treatment monitoring continues via telemedicine with the Chinese care team. Bring all treatment records home for your local oncologist. Treatment summaries are provided in English.
For broader logistics, see our guides to what to expect when getting surgery abroad and the medical tourism checklist.
Most medical tourism guides focus on proton therapy, but China offers something rarer: heavy ion (carbon ion) therapy.
Carbon ions are heavier than protons, which means they deposit even more energy at the tumor site. This makes them more effective against radiation-resistant tumors. Only a handful of countries operate carbon ion facilities - Japan, Germany, Italy, Austria, and China.
The Gansu Wuwei Tumor Hospital is the only facility in the world operating 2 heavy ion systems simultaneously (opens in new tab), giving it the capacity to treat more patients with shorter wait times than any single system could handle.
For patients with radiation-resistant tumors (chordoma, chondrosarcoma, certain sarcomas, adenoid cystic carcinoma), heavy ion therapy is an option available at only a few centers globally. China's cost for heavy ion therapy is significantly below Japan and Germany. If your oncologist has suggested particle therapy and you're facing a $150,000+ bill in the US - or an even higher bill at a European or Japanese center - China's pricing at $45,000-$55,000 makes the trip worth evaluating.
Read more about cancer treatment options in China in our comprehensive cancer treatment guide.
Proton therapy costs $45,000-$55,000 for a full course in China versus $100,000-$200,000 in the US, according to Healtra (opens in new tab) and PubMed-published US pricing data (opens in new tab). That's a 60-70% savings. US per-session cash-pay prices range from $4,700-$6,700 with significant 5-10x variation across centers.
China operates 11-14 proton centers and 3 heavy ion centers as of 2026, with 12 more under construction, according to the Particle Therapy Co-Operative Group (PTCOG) (opens in new tab). The country is expected to reach 20 facilities within 5 years.
SPHIC has published peer-reviewed outcomes including: 100% 3-year overall survival for prostate cancer, 94.3% for major salivary gland tumors, 100% 2-year survival for chordoma/chondrosarcoma, and 95.9% 1-year survival for recurrent head/neck cancers. See the full table above with linked sources.
Treatment runs 4-8 weeks, with sessions 5 days per week. Each session lasts 15-30 minutes including setup, with the actual radiation taking 1-3 minutes. Hypofractionated prostate protocols can be as short as 5 sessions over 1-2 weeks. Plan for a total in-country stay of 5-9 weeks.
US insurance coverage for proton therapy is inconsistent. Many insurers approve it for pediatric cancers and certain skull base tumors but deny coverage for prostate, breast, and other common cancers. If your insurer denies coverage or you're paying out of pocket, China's pricing at 60-70% below US rates makes international treatment a serious financial consideration.
Proton therapy reduces radiation exposure to healthy tissue surrounding the tumor. For cancers near critical structures (brain, spine, eyes, heart), this translates to fewer side effects without sacrificing tumor control. For some common cancers, proton therapy may not offer a meaningful advantage over modern IMRT. Your oncologist can advise whether your specific case benefits from proton therapy.
Proton therapy is one of the most expensive cancer treatments available. In the US, a single course can cost more than a house. In China, the same treatment - at facilities with published, peer-reviewed outcomes - costs 60-70% less.
If you or a family member has been recommended for proton or heavy ion therapy, get a quote from a Chinese center before committing to US pricing. The remote evaluation is free or low-cost, and it gives you a baseline to compare.
Compare cancer treatment costs across destinations →
This article is for informational purposes only and does not constitute medical advice. Treatment outcomes vary by cancer type, stage, and individual patient factors. Consult your oncologist before making treatment decisions.
Connect with world-class healthcare providers and explore treatment options tailored to your needs.
Expert network
Top providers worldwide
Verified credentials
Quality assured
Transparent pricing
Compare costs
